SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors react to a significant dip in operating earnings and insurance underwriting profits during the company's final quarter under Warren Buffett's leadership. The community is actively debating the company's massive cash hoard, with many expressing frustration over the lack of aggressive capital deployment or dividend payouts compared to broader market gains.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense volatility driven by a controversial short commentary from Michael Burry, which alleges that Anthropic poses an existential threat to its market share. While some investors fear this signals a potential valuation re-rating, many in the community are dismissing the negative sentiment as market manipulation, arguing that Palantir's specialized role in government and enterprise integration remains uniquely defensible.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is facing intense market skepticism as persistent AI-related growth concerns and sector-wide weakness weigh on its share price despite the execution of a historic twenty-five billion dollar accelerated share buyback. Investors are actively debating whether this volatility represents a generational buying opportunity for a fundamental leader or a structural trap as software platforms face increased pressure from emerging AI agentic workflows.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing high trading volatility as investors weigh strong backlog and booking momentum against lackluster quarterly results. The community remains deeply divided, with bulls pointing to the company's critical role in AI, silicon photonics, and hyperscale supply chains, while bears aggressively highlight dilution concerns, stagnant revenue growth, and high valuations.

Metals Royalty Co Inc. engages in the acquisition and management of critical metals and mineral royalties, streams, and other similar interests. The firm focuses on providing capital to support mineral security and independence in North America in support of accelerating domestic industry growth, including energy, defense and re-industrialization. It operates through Metal and Minerals, and Oil and Gas segments. The company was founded on October 27, 2022, and is headquartered in Calgary, Canada.

Metals Royalty Co Inc. (The)

The Metals Royalty Company

TMCR is capturing investor attention following its recent Nasdaq listing, with the community actively debating its valuation relative to its parent company, TMC the metals company. Discussions center on its role as a royalty play on deep-sea mineral assets and whether the low available float will lead to significant volatility or long-term value.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is gaining significant traction as community members highlight a series of high-profile partnerships, including collaborations with major asset managers and upcoming testnet milestones. Investors are closely monitoring the project's ability to facilitate cross-chain automation, fueling speculative optimism regarding potential exchange listings and its role in the broader Ethereum ecosystem.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is seeing heightened interest following its acquisition by Rezolve AI, with community discussions focused on the integration of decentralized data infrastructure with enterprise payment rails and agentic AI. Traders are actively debating the token's long-term utility versus its short-term price volatility, while monitoring upcoming revenue pool updates and staking developments.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing significant volatility as investors debate the impact of AI on enterprise software, with recent earnings sparking concerns over margin guidance despite strong subscription revenue growth. While the community remains deeply divided between those viewing the pullback as a generational buying opportunity and others fearing long-term structural disruption, the stock remains a focal point for traders tracking the broader software sector's resilience.

Applied Digital Corporation

Applied Digital is at the center of intense market attention as investors weigh a significant earnings beat against concerns over high debt levels and the anticipation of major hyperscaler lease announcements. The community is actively debating the stock's long-term growth potential and potential for a short squeeze, balancing excitement over the company's AI infrastructure expansion with skepticism regarding management's execution on pending contracts.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors weigh a discounted buyout agreement by Garda Therapeutics for $18 per share plus a potential milestone payment. While the deal has triggered volatility, the community is actively debating the valuation and the 'go-shop' provision, which keeps hope alive for a potential superior bid.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data and analyses.</li><li>RP1 is Replimune’s lead product candidate.</li></ul>Shares of Replimune Group Inc (REPL) fell 15% on Wednesday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.If losses hold, REPL is on track for its worst session in nearly seven months.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>In late July 2025, the FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data, and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at extremely high levels. Retail chatter around the stock has increased 171% over the past seven days, Stocktwits data showed.A retail user said that the FDA might ask for a fresh trial for approval, pitching the chances for a green light from the agency at below 20%.<stembedurl>https://www.stocktwits.com/BioRocket/message/649736736</stembedurl>Yet another user dismissed concerns about trial design.<stembedurl>https://www.stocktwits.com/pblegend66/message/649729070</stembedurl>Another user opined that the stock can either triple or wipe out a majority of its value after the FDA decision.<stembedurl>https://www.stocktwits.com/LilJimmy007/message/649726397</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 7% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tron-taps-86-billion-stablecoin-liquidity-via-hyperlane-across-150-chains-after-justin-sun-s-ai-push/cZJf39TRIAk">TRON Taps $86 Billion Stablecoin Liquidity Via Hyperlane Across 150 Chains, After Justin Sun’s AI Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.

Equity

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.


Replimune Group (NASDAQ:REPL) Stock Price Down 6.7% Following Insider Selling

Replimune Group (NASDAQ:REPL) Shares Down 6.7% After Insider Selling...

Christopher Sarchi Sells 6,500 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the company's stock in a transaction on Thursday, April 2nd. The stock was sold at an average...

Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the firm's stock in a transaction on Thursday, April 2nd. The shares were sold at an average...

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.</li></ul> Shares of Replimune Group Inc (REPL) closed 11% higher on Thursday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">issued</a> a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that shareholders are setting up to be disappointed like the last time when RP1 was denied approval.<stembedurl>https://www.stocktwits.com/TopCharts/message/649353360</stembedurl>Yet another expressed doubts about the FDA approving the drug, opining that a fresh trial would be needed for the same.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/649347582</stembedurl>According to data from Koyfin, five of the seven analysts covering REPL stock rate it ‘Buy’ or higher while two rate it a ‘Hold’. The 12-month average price target on the stock is $12.86, representing a potential upside of about 53%. &nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-sbac-stock-rallying-today/cZ7UR5SRI8r">Why Is SBAC Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug

Replimune Group (NASDAQ:REPL) Shares Up 7.2% - Should You Buy?

Replimune Group (NASDAQ:REPL) Trading Up 7.2% - Time to Buy...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two...

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Stocktwits

Stocktwits Polls

Traders are intensely monitoring the April 10th FDA decision for signs of an impending CRL or breakthrough approval.

Investors are weighing the high-stakes potential for a 200% move up against the threat of a complete collapse toward $2-3.

Significant volume spikes and price weakness have fueled rumors that institutional insiders may have leaked the upcoming regulatory news.

Bears argue the trial design deficiencies that led to a previous rejection remain unaddressed, making approval unlikely.

Current Price	$5.89
Prev Close	$7.80
Open	$8.05
Dividend Yield	0.00%
50-Day Moving Average	$7.59
Beta	0.82
Avg. Volume	1.63M
PE Ratio	-2.18

52-Week High	$13.24
52-Week Low	$2.68
Market Capitalization	$644.07M
EPS (Annual)	-$3.07
Price to Book	2.95
Revenue Per Employee	$0.00

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REPL News

REPLReplimune Group Inc